- Home
- IT vs RPRX Comparison
IT vs RPRX Comparison
Compare IT & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IT | RPRX |
|---|---|---|
| Founded | 1979 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.8B | 16.7B |
| IPO Year | 1993 | 2020 |
Fundamental Metrics
Financial Performance| Metric | IT | RPRX |
|---|---|---|
| Price | $231.46 | $40.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 4 |
| Target Price | ★ $309.67 | $45.75 |
| AVG Volume (30 Days) | 823.6K | ★ 3.4M |
| Earning Date | 02-03-2026 | 02-11-2026 |
| Dividend Yield | N/A | ★ 2.34% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 11.49 | 1.75 |
| Revenue | ★ $6,459,775,000.00 | $2,349,844,000.00 |
| Revenue This Year | $6.71 | $37.66 |
| Revenue Next Year | $3.35 | $2.34 |
| P/E Ratio | ★ $20.63 | $22.90 |
| Revenue Growth | ★ 5.24 | 3.70 |
| 52 Week Low | $221.16 | $29.66 |
| 52 Week High | $584.01 | $41.70 |
Technical Indicators
Market Signals| Indicator | IT | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.21 | 57.64 |
| Support Level | $221.16 | $38.86 |
| Resistance Level | $252.63 | $40.58 |
| Average True Range (ATR) | 8.14 | 0.83 |
| MACD | -1.52 | -0.02 |
| Stochastic Oscillator | 33.78 | 57.67 |
Price Performance
Historical ComparisonAbout IT Gartner Inc.
Gartner Inc provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services. The company operates through three business segments, namely Research, Conferences and Consulting. The company generates majority of the revenue from Research segment.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.